Toll Free: 1-888-928-9744
Published: Jun, 2014 | Pages:
55 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
ChemoCentryx, Inc. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'ChemoCentryx, Inc. - Product Pipeline Review - 2014', provides an overview of the ChemoCentryx, Inc.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of ChemoCentryx, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of ChemoCentryx, Inc. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of ChemoCentryx, Inc.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the ChemoCentryx, Inc.'s pipeline products Reasons to buy - Evaluate ChemoCentryx, Inc.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of ChemoCentryx, Inc. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the ChemoCentryx, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of ChemoCentryx, Inc. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of ChemoCentryx, Inc. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of ChemoCentryx, Inc. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 5 List of Figures 5 ChemoCentryx, Inc. Snapshot 6 ChemoCentryx, Inc. Overview 6 Key Information 6 Key Facts 6 ChemoCentryx, Inc. - Research and Development Overview 7 Key Therapeutic Areas 7 ChemoCentryx, Inc. - Pipeline Review 10 Pipeline Products by Stage of Development 10 Pipeline Products - Monotherapy 11 ChemoCentryx, Inc. - Pipeline Products Glance 12 ChemoCentryx, Inc. - Clinical Stage Pipeline Products 12 Phase II Products/Combination Treatment Modalities 12 Phase I Products/Combination Treatment Modalities 13 ChemoCentryx, Inc. - Early Stage Pipeline Products 14 Preclinical Products/Combination Treatment Modalities 14 Discovery Products/Combination Treatment Modalities 15 ChemoCentryx, Inc. - Unknown Stage Pipeline Products 16 Unknown Products/Combination Treatment Modalities 16 ChemoCentryx, Inc. - Drug Profiles 17 CCX-140 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 CCX-168 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 CCX-354 20 Product Description 20 Mechanism of Action 20 R&D Progress 20 vercirnon sodium 21 Product Description 21 Mechanism of Action 21 R&D Progress 21 CCX-507 23 Product Description 23 Mechanism of Action 23 R&D Progress 23 CCX-872 24 Product Description 24 Mechanism of Action 24 R&D Progress 24 CCX-1378 25 Product Description 25 Mechanism of Action 25 R&D Progress 25 CCX-1641 26 Product Description 26 Mechanism of Action 26 R&D Progress 26 CCX-6239 27 Product Description 27 Mechanism of Action 27 R&D Progress 27 CCX-650 28 Product Description 28 Mechanism of Action 28 R&D Progress 28 CCX-771 29 Product Description 29 Mechanism of Action 29 R&D Progress 29 Small Molecule Antagonist Of CCR6 for Autoimmune and Inflammatory Disorders 30 Product Description 30 Mechanism of Action 30 R&D Progress 30 Small Molecule Antagonist Of CXCR6 for Autoimmune and Liver Diseases 31 Product Description 31 Mechanism of Action 31 R&D Progress 31 Small Molecule Antagonists Of CCR1 32 Product Description 32 Mechanism of Action 32 R&D Progress 32 Small Molecule to Antagonize CCR and CXCR for Oncology and Autoimmune Disease 33 Product Description 33 Mechanism of Action 33 R&D Progress 33 CCR2-3G 34 Product Description 34 Mechanism of Action 34 R&D Progress 34 CCR9-3G 35 Product Description 35 Mechanism of Action 35 R&D Progress 35 CCX-956 36 Product Description 36 Mechanism of Action 36 R&D Progress 36 ChemoCentryx, Inc. - Pipeline Analysis 37 ChemoCentryx, Inc. - Pipeline Products by Target 37 ChemoCentryx, Inc. - Pipeline Products by Route of Administration 39 ChemoCentryx, Inc. - Pipeline Products by Molecule Type 40 ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action 41 ChemoCentryx, Inc. - Recent Pipeline Updates 43 ChemoCentryx, Inc. - Dormant Projects 51 ChemoCentryx, Inc. - Discontinued Pipeline Products 52 Discontinued Pipeline Product Profiles 52 CCX-832 52 vercirnon sodium 52 ChemoCentryx, Inc. - Locations And Subsidiaries 53 Head Office 53 Appendix 54 Methodology 54 Coverage 54 Secondary Research 54 Primary Research 54 Expert Panel Validation 54 Contact Us 55 Disclaimer 55
List of Tables ChemoCentryx, Inc., Key Information 6 ChemoCentryx, Inc., Key Facts 6 ChemoCentryx, Inc. - Pipeline by Indication, 2014 8 ChemoCentryx, Inc. - Pipeline by Stage of Development, 2014 10 ChemoCentryx, Inc. - Monotherapy Products in Pipeline, 2014 11 ChemoCentryx, Inc. - Phase II, 2014 12 ChemoCentryx, Inc. - Phase I, 2014 13 ChemoCentryx, Inc. - Preclinical, 2014 14 ChemoCentryx, Inc. - Discovery, 2014 15 ChemoCentryx, Inc. - Unknown, 2014 16 ChemoCentryx, Inc. - Pipeline by Target, 2014 38 ChemoCentryx, Inc. - Pipeline by Route of Administration, 2014 39 ChemoCentryx, Inc. - Pipeline by Molecule Type, 2014 40 ChemoCentryx, Inc. - Pipeline Products by Mechanism of Action, 2014 42 ChemoCentryx, Inc. - Recent Pipeline Updates, 2014 43 ChemoCentryx, Inc. - Dormant Developmental Projects,2014 51 ChemoCentryx, Inc. - Discontinued Pipeline Products, 2014 52
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.